RXi Pharmaceuticals Corporation (NASDAQ:RXII) is scheduled to announce its earnings results after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). During the same quarter in the prior year, the firm posted ($0.34) earnings per share. On average, analysts expect RXi Pharmaceuticals Corporation to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

RXi Pharmaceuticals Corporation (RXII) opened at $0.57 on Monday.

In other RXi Pharmaceuticals Corporation news, insider Alexey Eliseev sold 176,800 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $0.54, for a total value of $95,472.00. Following the completion of the transaction, the insider now owns 1,100,931 shares in the company, valued at approximately $594,502.74. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.71% of the stock is currently owned by corporate insiders.

WARNING: “RXi Pharmaceuticals Corporation (RXII) to Release Quarterly Earnings on Wednesday” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.watchlistnews.com/rxi-pharmaceuticals-corporation-rxii-to-release-quarterly-earnings-on-wednesday/1681947.html.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Earnings History for RXi Pharmaceuticals Corporation (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.